Hubbry Logo
DimetofrineDimetofrineMain
Open search
Dimetofrine
Community hub
Dimetofrine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Dimetofrine
from Wikipedia
Dimetofrine
Clinical data
Trade namesDovida, Pressamina, Superten
Other namesDimethophrine; Dimetrophine; Dimethofrine; DMP; SM-14; 3,5-Dimethoxy-4,β-dihydroxy-N-methylphenethylamine; 3,5-Dimethoxy-4,β-dihydroxy-N-methyl-β-phenylethylamine
Routes of
administration
Oral[1]
Drug classα1-Adrenergic receptor agonist; Antihypotensive agent; Vasopressor
ATC code
Identifiers
  • (RS)-4-[1-Hydroxy-2-(methylamino)ethyl]-2,6-dimethoxyphenol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.041.210 Edit this at Wikidata
Chemical and physical data
FormulaC11H17NO4
Molar mass227.260 g·mol−1
3D model (JSmol)
  • O(c1cc(cc(OC)c1O)C(O)CNC)C
  • InChI=1S/C11H17NO4/c1-12-6-8(13)7-4-9(15-2)11(14)10(5-7)16-3/h4-5,8,12-14H,6H2,1-3H3 checkY
  • Key:ZKGDBJAHIIXDDW-UHFFFAOYSA-N checkY
  (verify)

Dimetofrine (INNTooltip International Nonproprietary Name), also known as dimethophrine or dimetophrine and sold under the brand names Dovida, Pressamina, and Superten, is a medication described as a sympathomimetic, vasoconstrictor, and cardiac stimulant.[2][3][4] It is said to be similarly or less effective than midodrine in the treatment of orthostatic hypotension and shows substantially lower potency.[5][1]

The drug is a selective α1-adrenergic receptor agonist[6] but is also said to have β-adrenergic receptor agonist activity.[1] It is a substituted phenethylamine and is also known as 3,5-dimethoxy-4,β-dihydroxy-N-methylphenethylamine.[2] Its chemical structure is similar to that of desglymidodrine (3,6-dimethoxy-β-hydroxyphenethylamine), the active metabolite of midodrine.[5]

Dimetofrine remained marketed only in Italy in 2000.[3]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
Add your contribution
Related Hubs
User Avatar
No comments yet.